Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$35.38 +0.9%	$36.33	$23.42 ▼ $62.58	$2.04B	0.8	1.06 million shs	384,237 shs
BHC Bausch Health Cos	$7.01 +5.2%	$6.20	$4.25 ▼ $9.85	$2.47B	0.41	1.81 million shs	3.80 million shs
DNLI Denali Therapeutics	$13.22 -5.0%	$14.29	$10.57 ▼ $33.33	$2.02B	1.36	1.69 million shs	2.01 million shs
KROS Keros Therapeutics	$13.71 +2.7%	$13.98	$9.12 ▼ $72.37	$542.22M	1.33	447,641 shs	305,989 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-1.83%	-2.92%	-10.10%	+22.14%	-19.67%
BHC Bausch Health Cos	+15.70%	+15.60%	+3.83%	+42.96%	+23.17%
DNLI Denali Therapeutics	-0.34%	-3.65%	-4.18%	-2.43%	-37.86%
KROS Keros Therapeutics	-2.77%	-8.69%	-7.55%	-0.89%	-70.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3005 of 5 stars	3.4	1.0	4.3	3.9	0.8	1.9
BHC Bausch Health Cos	4.542 of 5 stars	3.0	5.0	4.0	1.9	3.3	1.3
DNLI Denali Therapeutics	4.1938 of 5 stars	3.6	1.0	4.7	3.4	3.3	0.0
KROS Keros Therapeutics	2.6163 of 5 stars	3.3	2.0	0.0	2.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	59.22% Upside
BHC Bausch Health Cos	2.00	Hold	$9.00	28.48% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.85	156.02% Upside
KROS Keros Therapeutics	2.50	Moderate Buy	$30.00	118.82% Upside

Current Analyst Ratings Breakdown

Latest KROS, AGIO, BHC, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
6/10/2025	KROS Keros Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$32.00 ➝ $18.00
5/30/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/12/2025	KROS Keros Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$41.00 ➝ $26.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	56.32	N/A	N/A	$23.57 per share	1.50
BHC Bausch Health Cos	$9.63B	0.27	$8.15 per share	0.86	$0.40 per share	17.51
DNLI Denali Therapeutics	$330.53M	5.81	N/A	N/A	$8.53 per share	1.55
KROS Keros Therapeutics	$3.55M	156.87	N/A	N/A	$17.40 per share	0.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.22	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
BHC Bausch Health Cos	-$46M	$0.26	26.94	1.50	N/A	0.99%	-852.36%	5.25%	10/29/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-39.15%	-35.06%	N/A
KROS Keros Therapeutics	-$187.35M	$0.31	44.23	N/A	1.19	8.06%	2.96%	2.74%	N/A

Latest KROS, AGIO, BHC, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	DNLI Denali Therapeutics	-$0.74	-$0.72	+$0.02	-$0.72	$5.64 million	N/A
8/6/2025	Q2 2025	KROS Keros Therapeutics	-$1.14	-$0.76	+$0.38	-$0.76	$3.83 million	$0.02 million
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.97	$0.90	-$0.07	$0.40	$2.47 billion	$2.57 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
BHC Bausch Health Cos	141.90	1.31	0.98
DNLI Denali Therapeutics	N/A	9.56	9.56
KROS Keros Therapeutics	N/A	21.11	21.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
BHC Bausch Health Cos	78.65%
DNLI Denali Therapeutics	92.92%
KROS Keros Therapeutics	71.56%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.93%
BHC Bausch Health Cos	8.12%
DNLI Denali Therapeutics	12.50%
KROS Keros Therapeutics	22.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.24 million	Optionable
BHC Bausch Health Cos	20,700	370.13 million	340.07 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
KROS Keros Therapeutics	100	40.62 million	31.31 million	Optionable

KROS, AGIO, BHC, and DNLI Headlines

Recent News About These Companies

Analysts’ Opinions Are Mixed on These Healthcare Stocks: AMN Healthcare Services (AMN), Keros Therapeutics (KROS) and Evolent Health (EVH)

August 11 at 11:46 PM | theglobeandmail.com

Keros Therapeutics (NASDAQ:KROS) Price Target Cut to $20.00 by Analysts at HC Wainwright

August 11 at 2:40 AM | americanbankingnews.com

William Blair Cuts Earnings Estimates for Keros Therapeutics

August 11 at 2:01 AM | americanbankingnews.com

Leerink Partnrs Has Negative Estimate for KROS Q3 Earnings

August 11 at 2:58 AM | marketbeat.com

William Blair Predicts Lower Earnings for Keros Therapeutics

August 11 at 2:58 AM | marketbeat.com

HC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00

August 9 at 9:31 AM | marketbeat.com

XTX Topco Ltd Acquires New Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

August 9 at 3:36 AM | marketbeat.com

Keros prioritizes KER-065, pulls plug on cibotercept

August 8, 2025 | thepharmaletter.comT

Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2025 | zacks.com

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

August 6, 2025 | globenewswire.com

Keros Therapeutics Reports Second Quarter 2025 Financial Results

August 6, 2025 | globenewswire.com

Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $30.56

August 5, 2025 | americanbankingnews.com

Federated Hermes Inc. Grows Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

August 3, 2025 | marketbeat.com

Keros Therapeutics (KROS) Projected to Post Earnings on Wednesday

July 31, 2025 | marketbeat.com

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Moderate Buy" by Analysts

July 31, 2025 | marketbeat.com

KROS vs. EXAS: Which Stock Should Value Investors Buy Now?

July 28, 2025 | zacks.com

Corton Capital Inc. Makes New $186,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS)

July 28, 2025 | marketbeat.com

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

July 17, 2025 | globenewswire.com

B of A Securities Downgrades Keros Therapeutics (KROS)

June 11, 2025 | msn.com

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

June 10, 2025 | uk.finance.yahoo.com

3KROS : Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline...

June 10, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS, AGIO, BHC, and DNLI Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$35.38 +0.30 (+0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$35.38 +0.00 (+0.00%)

As of 07:43 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Bausch Health Cos NYSE:BHC

$7.00 +0.35 (+5.18%)

Closing price 03:59 PM Eastern

Extended Trading

$7.00 0.00 (-0.07%)

As of 07:31 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Denali Therapeutics NASDAQ:DNLI

$13.22 -0.70 (-5.03%)

Closing price 04:00 PM Eastern

Extended Trading

$13.15 -0.07 (-0.53%)

As of 07:55 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Keros Therapeutics NASDAQ:KROS

$13.71 +0.36 (+2.70%)

Closing price 04:00 PM Eastern

Extended Trading

$13.70 -0.01 (-0.04%)

As of 04:31 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time